Genetic CYP2C19 substudies of placebo-controlled RCTs of clopidogrel
| Genetic substudy . | Setting . | Comparisons . | CYP2C19*2,*3 RR† . | CYP2C19*1,*17 RR† . | P interaction† . |
|---|---|---|---|---|---|
| ACTIVE A91 (n = 1134) | AF | Aspirin + clopidogrel vs aspirin + placebo | 0.83 (0.54-1.28) | 0.73 (0.57-0.93) | .61 |
| CURE91 (n = 5016) | ACS | Aspirin + clopidogrel vs aspirin + placebo | 0.69 (0.49-0.96) | 0.74 (0.61-0.89) | .72 |
| CHARISMA92 (n = 4862) | Established or high risk atherosclerosis | Aspirin + clopidogrel vs aspirin + placebo | 1.47 (0.98-2.21) | 0.98 (0.75-1.28) | .10 |
| CLARITY-TIMI 2893 (n = 465) | STEMI and fibrinolytic | Aspirin + clopidogrel vs aspirin + placebo | 0.40 (0.15-1.10) | 0.55 (0.25-1.05) | .61 |
| Genetic substudy . | Setting . | Comparisons . | CYP2C19*2,*3 RR† . | CYP2C19*1,*17 RR† . | P interaction† . |
|---|---|---|---|---|---|
| ACTIVE A91 (n = 1134) | AF | Aspirin + clopidogrel vs aspirin + placebo | 0.83 (0.54-1.28) | 0.73 (0.57-0.93) | .61 |
| CURE91 (n = 5016) | ACS | Aspirin + clopidogrel vs aspirin + placebo | 0.69 (0.49-0.96) | 0.74 (0.61-0.89) | .72 |
| CHARISMA92 (n = 4862) | Established or high risk atherosclerosis | Aspirin + clopidogrel vs aspirin + placebo | 1.47 (0.98-2.21) | 0.98 (0.75-1.28) | .10 |
| CLARITY-TIMI 2893 (n = 465) | STEMI and fibrinolytic | Aspirin + clopidogrel vs aspirin + placebo | 0.40 (0.15-1.10) | 0.55 (0.25-1.05) | .61 |
AF, atrial fibrillation.
Estimates as reported by Holmes et al.29